FRA1E common fragile site breaks map within a 370 kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD)

Cancer Letters

Volumn 246, Issue 1-2, 2007, Pages 82-91

  Hormozian, Fabiola ^a   Schmitt, Jens Guido ^a   Sagulenko, Evgeny ^a   Schwab, Manfred ^a   Savelyeva, Larissa ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Common fragile sites; Dihydropyrimidine dehydrogenase; DPYD; FRA1E; Genomic instability

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; FLUOROURACIL;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CANCER PATIENT; CHROMOSOME 1P; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILE SITE; CHROMOSOME MAP; CHROMOSOME STRUCTURE; DATA BASE; DNA PROBE; DNA REPAIR; DNA SEQUENCE; DPYD GENE; ENZYME DEFICIENCY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FRA1E GENE; GENE; GENE DISRUPTION; GENE MAPPING; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APHIDICOLIN; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILE SITES; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; DIHYDROURACIL DEHYDROGENASE (NADP); HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES; MICROSATELLITE REPEATS; MUTATION;

EID: 33845625674     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.02.004     Document Type: Article

References (60)

1. Sutherland G.R., and Hecht F. Fragile Sites on Human Chromosomes (1985), Oxford University Press, New York
2. Glover T.W. Common fragile sites. Cancer Lett. 232 (2006) 4-12
3. Richards R.I. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet. 17 (2001) 339-345
4. Buttel I., Fechter A., and Schwab M. Common fragile sites and cancer, targeted cloning by insertional mutagenesis. Ann. NY Acad. Sci. 1028 (2004) 14-27
5. Glover T.W., Arlt M.F., Casper A.M., and Durkin S.G. Mechanisms of common fragile site instability. Hum. Mol. Genet. 14 (2005) 197-205
6. Yunis J.J., and Soreng A.L. Constitutive fragile sites and cancer. Science 226 (1984) 1199-1204
7. Hecht F., and Glover T.W. Cancer chromosome breakpoints and common fragile sites induced by aphidicolin. Cancer Genet. Cytogenet. 13 (1984) 185-188
8. Boldog F., Gemmill R.M., West J., Robinson M., Robinson L., Li E., et al. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum. Mol. Genet. 6 (1997) 193-203
9. Mimori K., Druck T., Inoue A.H., Berk L., Mori M., Huebner K., and Croce C.M. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. PNAS 96 (1999) 7456-7461
10. Michael D., Beer D.G., Wilke C.W., Miller D.E., and Glover T.W. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 15 (1997) 1653-1659
11. Morelli C., Karayianni E., Magnanini C., Mungall A.J., Thorland E., Negrini M., et al. Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumours. Oncogene 21 (2002) 7266-7276
12. Denison S.R., Callahan G., Becker N.A., Phillips L.A., and Smith D.I. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosom. Cancer 38 (2003) 40-52
13. Callahan G., Denison S.R., Phillips L.A., Shridhar V., and Smith D.I. Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene 22 (2003) 590-601
14. Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet. 9 (2000) 1651-1663
15. Mangelsdorf M., Ried K., Woollatt E., Dayan S., Eyre H., Finnis M., et al. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res. 60 (2000) 1683-1689
16. Finnis M., Dayan S., Hobson L., Chenevix-Trench G., Friend K., Ried K., et al. Common chromosomal fragile site FRA16D mutation in cancer cells. Hum. Mol. Genet. 14 (2005) 1341-1349
17. Arlt M.F., Miller D.E., Beer D.G., and Glover T.W. Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosom. Cancer 33 (2002) 82-92
18. Wilke C.M., Guo S.W., Hall B.K., Boldog F., Gemmill R.M., Chandrasekharappa S.C., et al. Multicolour FISH mapping of YAC clones in 3p14 and identification of YAC spanning both FRA3B and the t(3;8) associated with hereditary renal cell carcinoma. Genomics 22 (1994) 319-326
19. Krummel K.A., Roberts L.R., Kawakami M., Glover T.W., and Smith D.I. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69 (2000) 37-46
20. Hellman A., Zlotorynski E., Scherer S.W., Cheung J., Vincent J.B., Smith D.I., et al. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 1 (2002) 89-97
21. Ciullo M., Debily M.A., Rozier L., Autiero M., Billault A., Mayau V., et al. Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I. Hum. Mol. Genet. 11 (2002) 2887-2894
22. Wilke C.M., Hall B.K., Hoge A., Pardee W., Smith D.I., and Glover T.W. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum. Mol. Genet. 5 (1996) 187-195
23. Thorland E.C., Myers S.L., Persing D.H., Sarkar G., McGovern R.M., Gostout B.S., and Smith D.I. Human papillomavirus type 16 integrations in cervical tumours frequently occur in common fragile sites. Cancer Res. 1 (2000) 5916-5921
24. Thorland E.C., Myers S.L., Gostout B.S., and Smith D.I. Common fragile sites are preferential targets for HPV16 integrations in cervical tumours. Oncogene 22 (2003) 1225-1237
25. Ferber M.J., Thorland E.C., Brink A.A., Rapp A.K., Phillips L.A., McGovern R., et al. Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma. Oncogene 22 (2003) 7233-7242
26. Glover T.W., Berger C., Coyle J., and Echo B. DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum. Genet. 67 (1984) 136-142
27. O'Keefe L.V., and Richards R.I. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett. 232 (2006) 37-47
28. Schwartz M., Zlotorynski E., and Kerem B. The molecular basis of common and rare fragile sites. Cancer Lett. 232 (2006) 13-26
29. Savelyeva L., Sagulenko E., Schmitt J.G., and Schwab M. The neurobeachin gene spans the common fragile site FRA13A. Hum. Genet. 118 (2006) 551-558
30. Mishmar D., Rahat A., Scherer S.W., Nyakatura G., Hinzmann B., Kohwi Y., et al. Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of an SV40 integration site. PNAS 95 (1998) 8141-8146
31. Zlotorynski E., Rahat A., Skaug J., Ben-Porat N., Ozeri E., Hershberg R., et al. Molecular basis for expression of common and rare fragile sites. Mol. Cell. Biol. 23 (2003) 7143-7151
32. Limongi M.Z., Pelliccia F., and Rocchi A. Characterization of the human common fragile site FRA2G. Genomics 81 (2003) 93-97
33. Le Beau M.M., Rassool F.V., Neilly M.E., Espinosa R., Glover T.W., Smith D.I., and McKeithan T.W. Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum. Mol. Genet. 7 (1998) 755-761
34. Wang L., Darling J., Zhang J.S., Huang H., Liu W., and Smith D.I. Allele-specific late replication and fragility of the most active common fragile site, FRA3B. Hum. Mol. Genet. 8 (1999) 431-437
35. Hellman A., Rahat A., Scherer S.W., Darvasi A., Tsui L.C., and Kerem B. Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol. Cell. Biol. 20 (2000) 4420-4427
36. Casper A.M., Nghiem P., Arlt M.F., and Glover T.W. ATR regulates fragile site stability. Cell 111 (2002) 779-789
37. Arlt M.F., Xu B., Durkin S.G., Casper A.M., Kastan M.B., and Glover T.W. BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. Mol. Cell. Biol. 24 (2004) 6701-6709
38. Musio A., Montagna C., Mariani T., Tilenni M., Focarelli M.L., Brait L., et al. SMC1 involvement in fragile site expression. Hum. Mol. Genet. 14 (2005) 525-533
39. Howlett N.G., Taniguchi T., Durkin S.G., D'Andrea A.D., and Glover T.W. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum. Mol. Genet. 14 (2005) 693-701
40. Smith D.I., Huang H., and Wang L. Common fragile sites and cancer. Int. J. Oncol. 12 (1998) 187-196
41. Smith D.I., Zhu Y., McAvory S., and Kuhn R. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett. 232 (2006) 48-57
42. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84 (1996) 587-597
43. Huebner K., and Croce C.M. FRA3B and other common fragile sites: the weakest links. Nat. Rev. Cancer 1 (2001) 214-221
44. Cesari R., Martin E.S., Calin G.A., Pentimalli F., Bichi R., McAdams H., et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumour suppressor gene on chromosome 6q25-q27. PNAS 100 (2003) 5956-5961
45. Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., Bergsagel P.L., Kiguchi K., et al. WWOX, the FRA16D gene, behaves as a suppressor of tumour growth. Cancer Res. 61 (2001) 8068-8073
46. Savelyeva L., Sagulenko E., Schmitt J.G., and Schwab M. Low-frequency common fragile sites: link to neuropsychiatric disorders?. Cancer Lett. 232 (2006) 58-69
47. Matzner I., Savelyeva L., and Schwab M. Preferential integration of a transfected marker gene into spontaneously expressed fragile sites of a breast cancer cell line. Cancer Lett. 189 (2003) 207-219
48. Henegariu O., Bray-Ward P., and Ward D.C. Custom fluorescent-nucleotide synthesis as an alternative method for nucleic acid labeling. Nat. Biotechnol. 18 (2000) 345-348
49. Munteanu M.G., Vlahovicek K., Parthasarathy S., Simon I., and Pongor S. Rod models of DNA: sequence-dependent anisotropic elastic modeling of local bending phenomena. Trends Biochem. Sci. 23 (1998) 341-347
50. Wei X., Elizondo G., Sapone A., McLeod H.L., Raunio H., Fernandez-Salguero P., and Gonzalez F.J. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51 (1998) 391-400
51. Smit A.F. Interspersed repeats and other mementos of transposable elements in mammalian genomes. Curr. Opin. Genet. Dev. 9 (1999) 657-663
52. El-Achkar E., Gebault-Seurea M., Muleris M., Dutrillaux B., and Debatisse M. Premature condensation induces breaks at the interface of early and late replicating chromosome bands bearing common fragile sites. PNAS 102 (2005) 18069-18074
53. Sutherland G.R. Rare fragile sites. Cytogenet. Genome Res. 100 (2003) 77-84
54. Van Kuilenburg B.P., Vreken P., Abeling N.G.G.M., Bakker H.D., Meinsma R., Van Lenthe H., et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet. 104 (1999) 1-9
55. van Gennip H., Abeling N.G.G.M., Vreken P., and van Kuilenburg A.B.P. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J. Inherit. Metab. Dis. 20 (1997) 203-213
56. Fiumara A., van Kuilenburg A.B.P., Caruso U., Nucifora C., Marzullo E., Barone R., et al. Dihydropyrimidine dehydrogenase deficiency and acute neurological presentation. J. Inherit. Metab. Dis. 26 (2003) 407-409
57. Al-Sanna'a N.A., Van Kuilenburg A.B.P., Atrak T.M., Abdul Jabbar M.A., and VanGennip A.H. Dihydropyrimidine dehydrogenase deficiency presenting at birth. J. Inherit. Metab. 28 (2005) 793-796
58. Ridge S.A., Sludden J., Brown O., Robertson L., Wei X., Sapone A., et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. J. Clin. Pharmacol. 46 (1998) 151-156
59. van Kuilenburg A.B.P. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40 (2004) 939-950
60. Van Kuilenburg B.P., Meinsma R., Zoetekouw L., and Van Gennip A.H. High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12 (2002) 555-558